Cargando…

Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role?

The mainstay of acute myocardial infarction has long been timely reperfusion of the culprit obstruction. Reperfusion injury resulting from a multitude of pathophysiological processes has been demonstrated to negatively affect myocardial recovery and function post-infarction. Adenosine interacts dire...

Descripción completa

Detalles Bibliográficos
Autores principales: De Marco, Corrado, Charron, Thierry, Rousseau, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140324/
https://www.ncbi.nlm.nih.gov/pubmed/35645815
http://dx.doi.org/10.3389/fphar.2022.856747
_version_ 1784715068214083584
author De Marco, Corrado
Charron, Thierry
Rousseau, Guy
author_facet De Marco, Corrado
Charron, Thierry
Rousseau, Guy
author_sort De Marco, Corrado
collection PubMed
description The mainstay of acute myocardial infarction has long been timely reperfusion of the culprit obstruction. Reperfusion injury resulting from a multitude of pathophysiological processes has been demonstrated to negatively affect myocardial recovery and function post-infarction. Adenosine interacts directly with the sequential pathophysiological processes culminating in reperfusion injury by inhibiting them upstream. The evidence for adenosine’s benefit in acute myocardial infarction has produced mixed results with regards to myocardial salvage and long-term mortality. The heterogenous evidence with regards to benefits on clinical outcomes has resulted in modest uptake of adenosine in the clinical setting. However, it is critical to analyze the variability in study methodologies. The goal of this review is to evaluate how adenosine dose, route of administration, timing of administration, and site of administration play essential roles in the molecule’s efficacy. The benefits of adenosine, as highlighted in the following review, are clear and its role in the treatment of acute myocardial infarction should not be discounted
format Online
Article
Text
id pubmed-9140324
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91403242022-05-28 Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role? De Marco, Corrado Charron, Thierry Rousseau, Guy Front Pharmacol Pharmacology The mainstay of acute myocardial infarction has long been timely reperfusion of the culprit obstruction. Reperfusion injury resulting from a multitude of pathophysiological processes has been demonstrated to negatively affect myocardial recovery and function post-infarction. Adenosine interacts directly with the sequential pathophysiological processes culminating in reperfusion injury by inhibiting them upstream. The evidence for adenosine’s benefit in acute myocardial infarction has produced mixed results with regards to myocardial salvage and long-term mortality. The heterogenous evidence with regards to benefits on clinical outcomes has resulted in modest uptake of adenosine in the clinical setting. However, it is critical to analyze the variability in study methodologies. The goal of this review is to evaluate how adenosine dose, route of administration, timing of administration, and site of administration play essential roles in the molecule’s efficacy. The benefits of adenosine, as highlighted in the following review, are clear and its role in the treatment of acute myocardial infarction should not be discounted Frontiers Media S.A. 2022-05-13 /pmc/articles/PMC9140324/ /pubmed/35645815 http://dx.doi.org/10.3389/fphar.2022.856747 Text en Copyright © 2022 De Marco, Charron and Rousseau. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
De Marco, Corrado
Charron, Thierry
Rousseau, Guy
Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role?
title Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role?
title_full Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role?
title_fullStr Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role?
title_full_unstemmed Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role?
title_short Adenosine in Acute Myocardial Infarction-Associated Reperfusion Injury: Does it Still Have a Role?
title_sort adenosine in acute myocardial infarction-associated reperfusion injury: does it still have a role?
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140324/
https://www.ncbi.nlm.nih.gov/pubmed/35645815
http://dx.doi.org/10.3389/fphar.2022.856747
work_keys_str_mv AT demarcocorrado adenosineinacutemyocardialinfarctionassociatedreperfusioninjurydoesitstillhavearole
AT charronthierry adenosineinacutemyocardialinfarctionassociatedreperfusioninjurydoesitstillhavearole
AT rousseauguy adenosineinacutemyocardialinfarctionassociatedreperfusioninjurydoesitstillhavearole